Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front Med    2013, Vol. 7 Issue (2) : 242-254     DOI: 10.1007/s11684-013-0256-4
Inflammation and liver tumorigenesis
Beicheng Sun1(), Michael Karin2()
1. Liver Transplantation Center of the First Affiliated Hospital and Cancer Center, Nanjing Medical University, Nanjing 210029, China; 2. Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology and Pathology, Cancer Center, UCSD School of Medicine, La Jolla, CA 92093-0723, USA
Download: PDF(318 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Inflammation has been considered as one of the hallmarks of cancer, and chronic hepatitis is a major cause of liver cancer. This review will focus on the pathogenic role of inflammation in hepatocarcinogenesis and will discuss recent advances in understanding the chronic hepatitis-liver cancer link based on hot spots in liver cancer research, including cellular interaction, cytokines, microRNA and stem cells. All of these mechanisms should be taken into consideration because they are crucial for the development of more efficacious therapeutic strategies for preventing and treating human chronic hepatitis and hepatocellular carcinoma.

Keywords hepatocellular carcinoma      hepatitis      cytokine      stem cell      miRNA     
Corresponding Authors: Sun Beicheng,; Karin Michael,   
Issue Date: 05 June 2013
URL:     OR
Fig.1  In the tumor or inflammation microenvironment of chronic hepatitis HCC, macrophages can be classified into type 1 or 2. Both of these types have a central function in modulating inflammation resolution and tumor promotion through interaction with lymphocyte subsets. Type I macrophages emerge in the very early stage of the tumor, recruiting inflammatory cells which mediate the Th1 and Th17 response and promote hepatic compensatory proliferation by cytokines, such as IL-6 and TNF-α. Type II macrophages emerge in the late stage of the tumor and are in charge of Th2 response by recruiting Th2 cells that contributed to immunosuppression. Aside from macrophages, MDSCs contributed an inmmunosuppressive effect during tumor development by secreting IL-10 and TGF-β. Moreover, angiogenesis can be enhanced in the tumor microenvironment due to the secretion of cytokines such as VEGF oriented from type II macrophages and MDSCs.
StudyDifferentially expressed miRNAs (no./total)Most significantly overexpressed miRNAs in hepatocellular carcinomaMost significantly underexpressed miRNAs in hepatocellular carcinoma
Jiang et al. [98]16/16miR-18, miR-21, miR-33, miR-135a, miR-221, miR-130bmiR-101, miR-139, miR-150, miR-199a, miR-199a*, miR-199b, miR-200b, miR-214, miR-223, miR-301
Kutay et al. [99]26/245miR-101b-2, miR-130, miR-130a, miR-172a-2, miR-219-1, miR-23a, miR-23b, miR-24, miR-328-1, let-7a-2, miR-103-2, miR-106, miR-106a-1, miR-106b-1, miR-130a-1, miR-17, miR-20, miR-20-1, miR-21, miR-21-1, miR-320-2, miR-93, miR-99bmiR-122, miR-123, miR-215
Murakami et al. [100]8/30miR-224, miR-18, miR-p18miR-199a*,miR-199a,miR-200a, miR-125a, miR-195
Li et al. [101]10/10miR-181a, miR-221, miR-222, miR-25, miR-34amiR-101,miR-148a,miR-424,miR-214, miR-29c
Wang et al. [102]22/157miR-224, miR-182, miR-183, miR-96, miR-9*, miR-9, miR-222, miR-216, miR-21, miR-186, miR-301, miR-221, miR-155,miR-182*, miR-137, miR-25, miR-324-5p, miR-151, miR-374miR-214, miR-145, miR-139
Budhu et al. [103]20/20miR-338, miR-219-1, miR-207, miR-185miR-30c-1, miR-1-2, miR-34a, miR-19a, miR-148a, miR-124a-2, miR-9-2, miR-148b, miR-122a, miR-125b-2, miR-194, miR-30a, miR-126, miR-60,702.8m2, miR-30e, let-7g
Gramantieri et al. [104]33/35miR-221let-7a-1, let-7a-2, let-7a-3, let-7b, let-7c, let-7d, let-7e, let-7f-2, let-7g, miR-122a, miR-124a-2, miR-130a, miR-132,miR-136, miR-141, miR-142, miR-143, miR-145, miR-146, miR-150, miR-155(BIC), miR-181a-1, miR-181a-2, miR-181c, miR-195, miR-199a-1-5p, miR-199a-2-5p, miR-199b, miR-200b, miR-214, miR-223, mir-594
Varnholt et al. [105]5/80miR-122, miR-100, miR-10amiR-198 and miR-145
Wong et al. [106]2/2miR-222miR-223
Pineau et al. [107]12/70miR-106b, miR-21, miR-210, miR-221, miR-222, miR-224, miR-34a, miR-425, miR-519a, miR-93, miR-96let-7c
Tab.1  Summary of microRNA expression in hepatocellular carcinoma
1 Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008; 27(45): 5904-5912
doi: 10.1038/onc.2008.271 pmid:18836471
2 Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359(19): 1995-2004
doi: 10.1056/NEJMoa0804525 pmid:18923165
3 Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006; 25(27): 3834-3847
doi: 10.1038/sj.onc.1209562 pmid:16799625
4 Sweet MJ, Hume DA. Endotoxin signal transduction in macrophages. J Leukoc Biol 1996; 60(1): 8-26
5 Yan S, Wang L, Liu N, Wang Y, Chu Y. Critical role of interleukin-17/interleukin-17 receptor axis in mediating Con A-induced hepatitis. Immunol Cell Biol 2012; 90(4): 421-428
6 Hsieh WT, Tsai CT, Wu JB, Hsiao HB, Yang LC, Lin WC. Kinsenoside, a high yielding constituent from Anoectochilus formosanus, inhibits carbon tetrachloride induced Kupffer cells mediated liver damage. J Ethnopharmacol 2011; 135(2): 440-449
doi: 10.1016/j.jep.2011.03.040 pmid:21470577
7 Ramaiah SK, Jaeschke H. Role of neutrophils in the pathogenesis of acute inflammatory liver injury. Toxicol Pathol 2007; 35(6): 757-766
doi: 10.1080/01926230701584163 pmid:17943649
8 Jaeschke H, Hasegawa T. Role of neutrophils in acute inflammatory liver injury. Liver Int 2006; 26(8): 912-919
doi: 10.1111/j.1478-3231.2006.01327.x pmid:16953830
9 Jaeschke H, Farhood A. Neutrophil and Kupffer cell-induced oxidant stress and ischemia-reperfusion injury in rat liver. Am J Physiol 1991; 260(3 Pt 1): G355-G362
10 Lee WM. Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. Hepatology 2004; 40(1): 6-9
doi: 10.1002/hep.20293 pmid:15239078
11 Knolle PA, Gerken G. Local control of the immune response in the liver. Immunol Rev 2000;174:21-34
12 Ishida Y, Kondo T, Ohshima T, Fujiwara H, Iwakura Y, Mukaida N. A pivotal involvement of IFN-gamma in the pathogenesis of acetaminophen-induced acute liver injury. FASEB J 2002; 16(10): 1227-1236
doi: 10.1096/fj.02-0046com pmid:12153990
13 Liu ZX, Govindarajan S, Kaplowitz N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology 2004; 127(6): 1760-1774
doi: 10.1053/j.gastro.2004.08.053 pmid:15578514
14 Arshad MI, Rauch M, L’helgoualc’h A, Julia V, Leite-de-Moraes MC, Lucas-Clerc C, Piquet-Pellorce C, Samson M. NKT cells are required to induce high IL-33 expression in hepatocytes during ConA-induced acute hepatitis. Eur J Immunol 2011; 41(8): 2341-2348
doi: 10.1002/eji.201041332 pmid:21557213
15 Bissell DM, Wang SS, Jarnagin WR, Roll FJ. Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest 1995; 96(1): 447-455
doi: 10.1172/JCI118055 pmid:7615817
16 Knolle PA, L?ser E, Protzer U, Duchmann R, Schmitt E, zum Büschenfelde KH, Rose-John S, Gerken G. Regulation of endotoxin-induced IL-6 production in liver sinusoidal endothelial cells and Kupffer cells by IL-10. Clin Exp Immunol 1997; 107(3): 555-561
doi: 10.1046/j.1365-2249.1997.d01-959.x pmid:9067532
17 Knolle PA, Germann T, Treichel U, Uhrig A, Schmitt E, Hegenbarth S, Lohse AW, Gerken G. Endotoxin down-regulates T cell activation by antigen-presenting liver sinusoidal endothelial cells. J Immunol 1999; 162(3): 1401-1407
18 Knolle PA, Limmer A. Neighborhood politics: the immunoregulatory function of organ-resident liver endothelial cells. Trends Immunol 2001; 22(8): 432-437
doi: 10.1016/S1471-4906(01)01957-3 pmid:11473832
19 Knolle PA, Uhrig A, Hegenbarth S, L?ser E, Schmitt E, Gerken G, Lohse AW. IL-10 down-regulates T cell activation by antigen-presenting liver sinusoidal endothelial cells through decreased antigen uptake via the mannose receptor and lowered surface expression of accessory molecules. Clin Exp Immunol 1998; 114(3): 427-433
doi: 10.1046/j.1365-2249.1998.00713.x pmid:9844054
20 Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol 2009; 27: 147-163
21 Kojima N, Sato M, Suzuki A, Sato T, Satoh S, Kato T, Senoo H. Enhanced expression of B7-1, B7-2, and intercellular adhesion molecule 1 in sinusoidal endothelial cells by warm ischemia/reperfusion injury in rat liver. Hepatology 2001; 34(4): 751-757
doi: 10.1053/jhep.2001.27804 pmid:11584372
22 Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, Hussell T, Feldmann M, Udalova IA. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol 2011; 12(3): 231-238
doi: 10.1038/ni.1990 pmid:21240265
23 Chappell L, Kaiser P, Barrow P, Jones MA, Johnston C, Wigley P. The immunobiology of avian systemic salmonellosis. Vet Immunol Immunopathol 2009; 128(1-3): 53-59
doi: 10.1016/j.vetimm.2008.10.295 pmid:19070366
24 Larrubia JR, Benito-Martínez S, Calvino M, Sanz-de-Villalobos E, Parra-Cid T. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol 2008; 14(47): 7149-7159
doi: 10.3748/wjg.14.7149 pmid:19084927
25 Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214(2): 199-210
doi: 10.1002/path.2277 pmid:18161745
26 Movahedi K, Laoui D, Gysemans C, Baeten M, Stangé G, Van den Bossche J, Mack M, Pipeleers D, In’t Veld P, De Baetselier P, Van Ginderachter JA. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010; 70(14): 5728-5739
doi: 10.1158/0008-5472.CAN-09-4672 pmid:20570887
27 Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11(10): 889-896
doi: 10.1038/ni.1937 pmid:20856220
28 Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140(6): 883-899
doi: 10.1016/j.cell.2010.01.025 pmid:20303878
29 Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441(7092): 431-436
doi: 10.1038/nature04870 pmid:16724054
30 Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 2011; 7(5): 651-658
doi: 10.7150/ijbs.7.651 pmid:21647333
31 Chen S, Akbar SM, Abe M, Hiasa Y, Onji M. Immunosuppressive functions of hepatic myeloid-derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus. Clin Exp Immunol 2011; 166(1): 134-142
doi: 10.1111/j.1365-2249.2011.04445.x pmid:21762128
32 Hu CE, Gan J, Zhang RD, Cheng YR, Huang GJ. Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scand J Gastroenterol 2011; 46(2): 156-164
doi: 10.3109/00365521.2010.516450 pmid:20822377
33 Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Krüger C, Manns MP, Greten TF, Korangy F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008; 135(1): 234-243
doi: 10.1053/j.gastro.2008.03.020 pmid:18485901
34 Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, Lehner F, Manns MP, Greten TF, Korangy F. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 2009; 50(3): 799-807
doi: 10.1002/hep.23054 pmid:19551844
35 Grivennikov SI, Karin M. Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 2010; 20(1): 65-71
doi: 10.1016/j.gde.2009.11.004 pmid:20036794
36 Voloboueva LA, Giffard RG. Inflammation, mitochondria, and the inhibition of adult neurogenesis. J Neurosci Res 2011; 89(12): 1989-1996
doi: 10.1002/jnr.22768 pmid:21910136
37 Tawara K, Oxford JT, Jorcyk CL. Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res 2011;3:177-189
38 Tanaka T, Narazaki M, Kishimoto T. Therapeutic Targeting of the Interleukin-6 Receptor. Annu Rev Pharmacol Toxicol 2012; 52: 199-219
39 Mair M, Blaas L, Osterreicher CH, Casanova E, Eferl R. JAK-STAT signaling in hepatic fibrosis. Front Biosci 2011; 17: 2794-2811
40 Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011; 121(9): 3375-3383
doi: 10.1172/JCI57158 pmid:21881215
41 Erreni M, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) and inflammation in colorectal cancer. Cancer Microenviron 2011; 4(2): 141-154
doi: 10.1007/s12307-010-0052-5 pmid:21909876
42 Wang YC, Xu GL, Jia WD, Han SJ, Ren WH, Wang W, Liu WB, Zhang CH, Chen H. Estrogen suppresses metastasis in rat hepatocellular carcinoma through decreasing interleukin-6 and hepatocyte growth factor expression. Inflammation 2012; 35(1): 143-149
43 Jiang R, Deng L, Zhao L, Li X, Zhang F, Xia Y, Gao Y, Wang X, Sun B. miR-22 promotes HBV-related hepatocellular carcinoma development in males. Clin Cancer Res 2011; 17(17): 5593-5603
doi: 10.1158/1078-0432.CCR-10-1734 pmid:21750200
44 Hsu SH, Wang LT, Lee KT, Chen YL, Liu KY, Suen JL, Chai CY, Wang SN. Pro-inflammatory homeobox gene, ISX, regulates tumor growth and survival in hepatocellular carcinoma. Cancer Res Cancer Res 2013; 73(2): 508-518
45 Kroy DC, Beraza N, Tschaharganeh DF, Sander LE, Erschfeld S, Giebeler A, Liedtke C, Wasmuth HE, Trautwein C, Streetz KL. Lack of interleukin-6/glycoprotein 130/signal transducers and activators of transcription-3 signaling in hepatocytes predisposes to liver steatosis and injury in mice. Hepatology 2010; 51(2): 463-473
doi: 10.1002/hep.23322 pmid:19918973
46 Ando M, Uehara I, Kogure K, Asano Y, Nakajima W, Abe Y, Kawauchi K, Tanaka N. Interleukin 6 enhances glycolysis through expression of the glycolytic enzymes hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3. J Nippon Med Sch 2010; 77(2): 97-105
doi: 10.1272/jnms.77.97 pmid:20453422
47 Liu Y, Li PK, Li C, Lin J. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J Biol Chem 2010; 285(35): 27429-27439
doi: 10.1074/jbc.M110.142752 pmid:20562100
48 Alison MR, Nicholson LJ, Lin WR. Chronic inflammation and hepatocellular carcinoma. Recent Results Cancer Res 2011; 185: 135-148
49 Sander LE, Sackett SD, Dierssen U, Beraza N, Linke RP, Müller M, Blander JM, Tacke F, Trautwein C. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med 2010; 207(7): 1453-1464
doi: 10.1084/jem.20091474 pmid:20530204
50 Kushibiki S. Tumor necrosis factor-α-induced inflammatory responses in cattle. Anim Sci J 2011; 82(4): 504-511
doi: 10.1111/j.1740-0929.2011.00931.x pmid:21794006
51 Caminero A, Comabella M, Montalban X. Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: an ongoing story. J Neuroimmunol 2011; 234(1-2): 1-6
doi: 10.1016/j.jneuroim.2011.03.004 pmid:21474190
52 Shukla R, Yue J, Siouda M, Gheit T, Hantz O, Merle P, Zoulim F, Krutovskikh V, Tommasino M, Sylla BS. Proinflammatory cytokine TNF-α increases the stability of hepatitis B virus X protein through NF-κB signaling. Carcinogenesis 2011; 32(7): 978-985
doi: 10.1093/carcin/bgr057 pmid:21459755
53 Shi Z, Du C. Tumor necrosis factor alpha 308 G/A polymorphism and hepatocellular carcinoma risk in a Chinese population. Genet Test Mol Biomarkers 2011; 15(7-8): 569-572
doi: 10.1089/gtmb.2011.0008 pmid:21401328
54 Wang B, Wang J, Zheng Y, Zhou S, Zheng J, Wang F, Ma X, Zeng Z. A study of TNF-alpha-238 and-308 polymorphisms with different outcomes of persistent hepatitis B virus infection in China. Pathology 2010; 42(7): 674-680
doi: 10.3109/00313025.2010.523696 pmid:21080879
55 Chen KF, Tai WT, Liu TH, Huang HP, Lin YC, Shiau CW, Li PK, Chen PJ, Cheng AL. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res 2010; 16(21): 5189-5199
doi: 10.1158/1078-0432.CCR-09-3389 pmid:20884624
56 Xia L, Mo P, Huang W, Zhang L, Wang Y, Zhu H, Tian D, Liu J, Chen Z, Zhang Y, Chen Z, Hu H, Fan D, Nie Y, Wu K. The TNF-α/ROS/HIF-1-induced upregulation of FoxMI expression promotes HCC proliferation and resistance to apoptosis. Carcinogenesis 2012; 33(11): 2250-2259
doi: 10.1093/carcin/bgs249 pmid:22831955
57 Muntané J. Targeting cell death and survival receptors in hepatocellular carcinoma. Anticancer Agents Med Chem 2011; 11(6): 576-584
doi: 10.2174/187152011796011082 pmid:21554206
58 Kriegl L, Jung A, Engel J, Jackstadt R, Gerbes AL, Gallmeier E, Reiche JA, Hermeking H, Rizzani A, Bruns CJ, Kolligs FT, Kirchner T, G?ke B, De Toni EN. Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma. Clin Cancer Res 2010; 16(22): 5529-5538
doi: 10.1158/1078-0432.CCR-09-3403 pmid:20889918
59 Giannelli G, Mazzocca A, Fransvea E, Lahn M, Antonaci S. Inhibiting TGF-β signaling in hepatocellular carcinoma. Biochim Biophys Acta 2011; 1815(2): 214-223
60 Achyut BR, Yang L. Transforming growth factor-β in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology 2011; 141(4): 1167-1178
doi: 10.1053/j.gastro.2011.07.048 pmid:21839702
61 Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7(2): 131-142
doi: 10.1038/nrm1835 pmid:16493418
62 Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 2008; 47(6): 2059-2067
doi: 10.1002/hep.22283 pmid:18506891
63 Mamiya T, Yamazaki K, Masugi Y, Mori T, Effendi K, Du W, Hibi T, Tanabe M, Ueda M, Takayama T, Sakamoto M. Reduced transforming growth factor-beta receptor II expression in hepatocellular carcinoma correlates with intrahepatic metastasis. Lab Invest 2010; 90(9): 1339-1345
doi: 10.1038/labinvest.2010.105 pmid:20531292
64 Ito N, Kawata S, Tamura S, Shirai Y, Kiso S, Tsushima H, Matsuzawa Y. Positive correlation of plasma transforming growth factor-beta 1 levels with tumor vascularity in hepatocellular carcinoma. Cancer Lett 1995; 89(1): 45-48
doi: 10.1016/0304-3835(95)90156-6 pmid:7882301
65 Mazzocca A, Fransvea E, Lavezzari G, Antonaci S, Giannelli G. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology 2009; 50(4): 1140-1151
doi: 10.1002/hep.23118 pmid:19711426
66 Wu K, Ding J, Chen C, Sun W, Ning BF, Wen W, Huang L, Han T, Yang W, Wang C, Li Z, Wu MC, Feng GS, Xie WF, Wang HY. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology 2012; 56(6): 2255-2267
doi: 10.1002/hep.26007 pmid:22898879
67 Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6(11): 1133-1141
doi: 10.1038/ni1261 pmid:16200068
68 Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25: 821-852
69 Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity 2004; 21(4): 467-476
doi: 10.1016/j.immuni.2004.08.018 pmid:15485625
70 Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008; 8(5): 337-348
doi: 10.1038/nri2295 pmid:18408735
71 Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupé P, Barillot E, Soumelis V. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 2008; 9(6): 650-657
doi: 10.1038/ni.1613 pmid:18454150
72 Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008; 9(6): 641-649
doi: 10.1038/ni.1610 pmid:18454151
73 Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 2008; 205(11): 2491-2497
doi: 10.1084/jem.20072707 pmid:18936235
74 Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP, Zheng L. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009; 50(5): 980-989
doi: 10.1016/j.jhep.2008.12.033 pmid:19329213
75 Laan M, Cui ZH, Hoshino H, L?tvall J, Sj?strand M, Gruenert DC, Skoogh BE, Lindén A. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999; 162(4): 2347-2352
76 Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8(8): 618-631
doi: 10.1038/nrc2444 pmid:18633355
77 Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 2010; 51(1): 154-164
doi: 10.1002/hep.23291 pmid:19902483
78 Zhao Q, Xiao X, Wu Y, Wei Y, Zhu LY, Zhou J, Kuang DM. Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients. Eur J Immunol 2011; 41(8): 2314-2322
doi: 10.1002/eji.201041282 pmid:21674477
79 Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13(5): 715-725
doi: 10.1016/S1074-7613(00)00070-4 pmid:11114383
80 Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD, Cua DJ. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198(12): 1951-1957
doi: 10.1084/jem.20030896 pmid:14662908
81 Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, Powrie F, Maloy KJ. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med 2006; 203(11): 2473-2483
doi: 10.1084/jem.20061099 pmid:17030949
82 Lo CH, Chang CM, Tang SW, Pan WY, Fang CC, Chen Y, Wu PY, Chen KY, Ma HI, Xiao X, Tao MH. Differential antitumor effect of interleukin-12 family cytokines on orthotopic hepatocellular carcinoma. J Gene Med 2010; 12(5): 423-434
doi: 10.1002/jgm.1452 pmid:20440753
83 Hu P, Hu HD, Chen M, Peng ML, Tang L, Tang KF, Matsui M, Belladonna ML, Yoshimoto T, Zhang DZ, Xiang R, Ren H. Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Mol Immunol 2009; 46(8-9): 1654-1662
doi: 10.1016/j.molimm.2009.02.025 pmid:19299021
84 Li J, Lau G, Chen L, Yuan YF, Huang J, Luk JM, Xie D, Guan XY. Interleukin 23 promotes hepatocellular carcinoma metastasis via NF-kappa B induced matrix metalloproteinase 9 expression. PLoS ONE 2012; 7(9): e46264
doi: 10.1371/journal.pone.0046264 pmid:23050001
85 Jiang R, Tan Z, Deng L, Chen Y, Xia Y, Gao Y, Wang X, Sun B. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011; 54(3): 900-909
doi: 10.1002/hep.24486 pmid:21674558
86 Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld JC. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 2002; 277(37): 33676-33682
doi: 10.1074/jbc.M204204200 pmid:12087100
87 Zhang W, Chen Y, Wei H, Zheng C, Sun R, Zhang J, Tian Z. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res 2008; 14(20): 6432-6439
doi: 10.1158/1078-0432.CCR-07-4401 pmid:18927282
88 Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007; 27(4): 647-659
doi: 10.1016/j.immuni.2007.07.023 pmid:17919941
89 Park O, Wang H, Weng H, Feigenbaum L, Li H, Yin S, Ki SH, Yoo SH, Dooley S, Wang FS, Young HA, Gao B. In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression. Hepatology 2011; 54(1): 252-261
doi: 10.1002/hep.24339 pmid:21465510
90 Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol 2012; 39(4): 410-433
doi: 10.1053/j.seminoncol.2012.05.001 pmid:22846859
91 Hu J, Xu Y, Hao J, Wang S, Li C, Meng S. MiR-122 in hepatic function and liver diseases. Protein Cell 2012; 3(5): 364-371
doi: 10.1007/s13238-012-2036-3 pmid:22610888
92 Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116(2): 281-297
doi: 10.1016/S0092-8674(04)00045-5 pmid:14744438
93 He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5(7): 522-531
doi: 10.1038/nrg1379 pmid:15211354
94 Sugatani T, Hruska KA. Down-regulation of miR-21 biogenesis by estrogen action contributes to osteoclastic apoptosis. J Cell Biochem 2012; n/a
doi: 10.1002/jcb.24471 pmid:23238785
95 Mott JL. MicroRNAs involved in tumor suppressor and oncogene pathways: implications for hepatobiliary neoplasia. Hepatology 2009; 50(2): 630-637
doi: 10.1002/hep.23010 pmid:19585622
96 Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008; 47(6): 1955-1963
doi: 10.1002/hep.22256 pmid:18433021
97 Braconi C, Patel T. MicroRNA expression profiling: a molecular tool for defining the phenotype of hepatocellular tumors. Hepatology 2008; 47(6): 1807-1809
doi: 10.1002/hep.22326 pmid:18506877
98 Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, Roberts LR, Schmittgen TD. Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008; 14(2): 419-427
doi: 10.1158/1078-0432.CCR-07-0523 pmid:18223217
99 Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W, Jacob ST, Ghoshal K. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006; 99(3): 671-678
doi: 10.1002/jcb.20982 pmid:16924677
100 Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25(17): 2537-2545
doi: 10.1038/sj.onc.1209283 pmid:16331254
101 Li W, Xie L, He X, Li J, Tu K, Wei L, Wu J, Guo Y, Ma X, Zhang P, Pan Z, Hu X, Zhao Y, Xie H, Jiang G, Chen T, Wang J, Zheng S, Cheng J, Wan D, Yang S, Li Y, Gu J. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer 2008; 123(7): 1616-1622
doi: 10.1002/ijc.23693 pmid:18649363
102 Wang Y, Lee AT, Ma JZ, Wang J, Ren J, Yang Y, Tantoso E, Li KB, Ooi LL, Tan P, Lee CG. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 2008; 283(19): 13205-13215
doi: 10.1074/jbc.M707629200 pmid:18319255
103 Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, Zanetti KA, Ye QH, Qin LX, Croce CM, Tang ZY, Wang XW. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008; 47(3): 897-907
doi: 10.1002/hep.22160 pmid:18176954
104 Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, Calin GA, Giovannini C, Ferrazzi E, Grazi GL, Croce CM, Bolondi L, Negrini M. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007; 67(13): 6092-6099
doi: 10.1158/0008-5472.CAN-06-4607 pmid:17616664
105 Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, Odenthal M. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008; 47(4): 1223-1232
doi: 10.1002/hep.22158 pmid:18307259
106 Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF, Wong N. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 2008; 135(1): 257-269
doi: 10.1053/j.gastro.2008.04.003 pmid:18555017
107 Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM, Dejean A. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA 2010; 107(1): 264-269
doi: 10.1073/pnas.0907904107 pmid:20018759
108 Fan CG, Wang CM, Tian C, Wang Y, Li L, Sun WS, Li RF, Liu YG. miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3. Oncol Rep 2011; 26(5): 1281-1286
109 Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, David M. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007; 449(7164): 919-922
doi: 10.1038/nature06205 pmid:17943132
110 Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 2005; 309(5740): 1577-1581
doi: 10.1126/science.1113329 pmid:16141076
111 Zhang X, Zhang E, Ma Z, Pei R, Jiang M, Schlaak JF, Roggendorf M, Lu M. Modulation of hepatitis B virus replication and hepatocyte differentiation by microRNA-1. Hepatology 2011; 53(5): 1476-1485
doi: 10.1002/hep.24195 pmid:21520166
112 Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 2009; 15(1): 31-33
doi: 10.1038/nm.1902 pmid:19122656
113 van der Poorten D, George J. Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. Clin Liver Dis 2008; 12(4): 805-824, ix (ix.)
doi: 10.1016/j.cld.2008.07.003 pmid:18984468
114 Whittaker R, Loy PA, Sisman E, Suyama E, Aza-Blanc P, Ingermanson RS, Price JH, McDonough PM. Identification of microRNAs that control lipid droplet formation and growth in hepatocytes via high-content screening. J Biomol Screen 2010; 15(7): 798-805
doi: 10.1177/1087057110374991 pmid:20639500
115 Zheng L, Lv GC, Sheng J, Yang YD. Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD. J Gastroenterol Hepatol 2010; 25(1): 156-163
doi: 10.1111/j.1440-1746.2009.05949.x pmid:19780876
116 Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW, Kellum JM, Min H, Luketic VA, Sanyal AJ. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 2008; 48(6): 1810-1820
doi: 10.1002/hep.22569 pmid:19030170
117 Song G, Sharma AD, Roll GR, Ng R, Lee AY, Blelloch RH, Frandsen NM, Willenbring H. MicroRNAs control hepatocyte proliferation during liver regeneration. Hepatology 2010; 51(5): 1735-1743
doi: 10.1002/hep.23547 pmid:20432256
118 Castro RE, Ferreira DM, Zhang X, Borralho PM, Sarver AL, Zeng Y, Steer CJ, Kren BT, Rodrigues CM. Identification of microRNAs during rat liver regeneration after partial hepatectomy and modulation by ursodeoxycholic acid. Am J Physiol Gastrointest Liver Physiol 2010; 299(4): G887-G897
doi: 10.1152/ajpgi.00216.2010 pmid:20689055
119 Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133(2): 647-658
doi: 10.1053/j.gastro.2007.05.022 pmid:17681183
120 Marquez RT, Wendlandt E, Galle CS, Keck K, McCaffrey AP. MicroRNA-21 is upregulated during the proliferative phase of liver regeneration, targets Pellino-1, and inhibits NF-kappaB signaling. Am J Physiol Gastrointest Liver Physiol 2010; 298(4): G535-G541
doi: 10.1152/ajpgi.00338.2009 pmid:20167875
121 Lowes KN, Brennan BA, Yeoh GC, Olynyk JK. Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am J Pathol 1999; 154(2): 537-541
doi: 10.1016/S0002-9440(10)65299-6 pmid:10027411
122 Libbrecht L, Desmet V, Van Damme B, Roskams T. Deep intralobular extension of human hepatic ‘progenitor cells’ correlates with parenchymal inflammation in chronic viral hepatitis: can ‘progenitor cells’ migrate? J Pathol 2000; 192(3): 373-378
doi: 10.1002/1096-9896(2000)9999:9999<::AID-PATH700>3.0.CO;2-5 pmid:11054721
123 Viebahn CS, Yeoh GC. What fires prometheus? The link between inflammation and regeneration following chronic liver injury. Int J Biochem Cell Biol 2008; 40(5): 855-873
doi: 10.1016/j.biocel.2007.11.025 pmid:18207446
124 Alison MR, Lovell MJ. Liver cancer: the role of stem cells. Cell Prolif 2005; 38(6): 407-421
doi: 10.1111/j.1365-2184.2005.00354.x pmid:16300653
125 Theise ND, Yao JL, Harada K, Hytiroglou P, Portmann B, Thung SN, Tsui W, Ohta H, Nakanuma Y. Hepatic ‘stem cell’ malignancies in adults: four cases. Histopathology 2003; 43(3): 263-271
doi: 10.1046/j.1365-2559.2003.01707.x pmid:12940779
126 Dumble ML, Croager EJ, Yeoh GC, Quail EA. Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma. Carcinogenesis 2002; 23(3): 435-445
doi: 10.1093/carcin/23.3.435 pmid:11895858
127 Korkaya H, Wicha MS. Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs 2007; 21(5): 299-310
doi: 10.2165/00063030-200721050-00002 pmid:17896836
128 Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea—a paradigm shift. Cancer Res 2006; 66(4): 1883-1890 ; discussion 1895-1896
129 Vermeulen L, De Sousa E Melo F, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, Sprick MR, Kemper K, Richel DJ, Stassi G, Medema JP. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010; 12(5): 468-476
doi: 10.1038/ncb2048 pmid:20418870
130 Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet 2009; 25(1): 30-38
doi: 10.1016/j.tig.2008.10.012 pmid:19054589
131 Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11(1): 69-82
doi: 10.1016/j.ccr.2006.11.020 pmid:17222791
132 Stauffer JK, Scarzello AJ, Andersen JB, De Kluyver RL, Back TC, Weiss JM, Thorgeirsson SS, Wiltrout RH. Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors. Cancer Res 2011; 71(7): 2718-2727
doi: 10.1158/0008-5472.CAN-10-2705 pmid:21324921
133 Schrader J, Gordon-Walker TT, Aucott RL, van Deemter M, Quaas A, Walsh S, Benten D, Forbes SJ, Wells RG, Iredale JP. Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology 2011; 53(4): 1192-1205
doi: 10.1002/hep.24108 pmid:21442631
134 Brunt EM, Blomenkamp K, Ahmed M, Ali F, Marcus N, Teckman J. Hepatic progenitor cell proliferation and liver injury in α-1-antitrypsin deficiency. J Pediatr Gastroenterol Nutr 2010; 51(5): 626-630
doi: 10.1097/MPG.0b013e3181e7ff55 pmid:20890217
135 Kitisin K, Shetty K, Mishra L, Johnson LB. Hepatocellular stem cells. Cancer Biomark 2007; 3(4-5): 251-262
136 Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K, Hara Y, Zeng SS, Hayashi T, Kondo M, Takatori H, Yamashita T, Mizukoshi E, Ikeda H, Zen Y, Takamura H, Wang XW, Kaneko S. Discrete nature of EpCAM(+) and CD90(+) cancer stem cells in human hepatocellular carcinoma. Hepatology 2012; 57(4):1484-97
137 Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, Zheng TS, Browning B, Michaelson JS, Baetscher M, Wang B, Bissell DM, Burkly LC. TWEAK induces liver progenitor cell proliferation. J Clin Invest 2005; 115(9): 2330-2340
doi: 10.1172/JCI23486 pmid:16110324
138 Fausto N. Tweaking liver progenitor cells. Nat Med 2005; 11(10): 1053-1054
doi: 10.1038/nm1005-1053 pmid:16211039
139 Akhurst B, Matthews V, Husk K, Smyth MJ, Abraham LJ, Yeoh GC. Differential lymphotoxin-beta and interferon gamma signaling during mouse liver regeneration induced by chronic and acute injury. Hepatology 2005; 41(2): 327-335
doi: 10.1002/hep.20520 pmid:15660390
140 Uchio K, Graham M, Dean NM, Rosenbaum J, Desmoulière A. Down-regulation of connective tissue growth factor and type I collagen mRNA expression by connective tissue growth factor antisense oligonucleotide during experimental liver fibrosis. Wound Repair Regen 2004; 12(1): 60-66
doi: 10.1111/j.1067-1927.2004.012112.x-1 pmid:14974966
141 Nakamura K, Nonaka H, Saito H, Tanaka M, Miyajima A. Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice. Hepatology 2004; 39(3): 635-644
doi: 10.1002/hep.20086 pmid:14999682
142 Brooling JT, Campbell JS, Mitchell C, Yeoh GC, Fausto N. Differential regulation of rodent hepatocyte and oval cell proliferation by interferon gamma. Hepatology 2005; 41(4): 906-915
doi: 10.1002/hep.20645 pmid:15799032
143 Gangaraju VK, Lin H. MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol 2009; 10(2): 116-125
doi: 10.1038/nrm2621 pmid:19165214
144 Osborne JD, Flatow J, Holko M, Lin SM, Kibbe WA, Zhu LJ, Danila MI, Feng G, and Chisholm RL. Annotating the human genome with Disease Ontology. BMC Genomics .2009;10Suppl 1(S6.
145 Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, Deng C, Wauthier E, Reid LM, Ye QH, Qin LX, Yang W, Wang HY, Tang ZY, Croce CM, Wang XW. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009; 50(2): 472-480
doi: 10.1002/hep.22989 pmid:19585654
[1] Nan Ding,Jiafei Xi,Yanming Li,Xiaoyan Xie,Jian Shi,Zhaojun Zhang,Yanhua Li,Fang Fang,Sihan Wang,Wen Yue,Xuetao Pei,Xiangdong Fang. Global transcriptome analysis for identification of interactions between coding and noncoding RNAs during human erythroid differentiation[J]. Front. Med., 2016, 10(3): 297-310.
[2] Xinsen Xu,Yanyan Zhou,Runchen Miao,Wei Chen,Kai Qu,Qing Pang,Chang Liu. Transcriptional modules related to hepatocellular carcinoma survival: coexpression network analysis[J]. Front. Med., 2016, 10(2): 183-190.
[3] Zhi Xu,Chunxiang Cao,Haiyan Xia,Shujing Shi,Lingzhi Hong,Xiaowei Wei,Dongying Gu,Jianmin Bian,Zijun Liu,Wenbin Huang,Yixin Zhang,Song He,Nikki Pui-Yue Lee,Jinfei Chen. Protein phosphatase magnesium-dependent 1δ is a novel tumor marker and target in hepatocellular carcinoma[J]. Front. Med., 2016, 10(1): 52-60.
[4] Yuting Tan,Han Liu,Saijuan Chen. Mutant DNA methylation regulators endow hematopoietic stem cells with the preleukemic stem cell property, a requisite of leukemia initiation and relapse[J]. Front. Med., 2015, 9(4): 412-420.
[5] Felice Ho-Ching Tsang,Sandy Leung-Kuen Au,Lai Wei,Dorothy Ngo-Yin Fan,Joyce Man-Fong Lee,Carmen Chak-Lui Wong,Irene Oi-Lin Ng,Chun-Ming Wong. MicroRNA-142-3p and microRNA-142-5p are downregulated in hepatocellular carcinoma and exhibit synergistic effects on cell motility[J]. Front. Med., 2015, 9(3): 331-343.
[6] Lanping Xu,Huanling Zhu,Jianda Hu,Depei Wu,Hao Jiang,Qian Jiang,Xiaojun Huang. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase[J]. Front. Med., 2015, 9(3): 304-311.
[7] Jianping Ye. Beneficial metabolic activities of inflammatory cytokine interleukin 15 in obesity and type 2 diabetes[J]. Front. Med., 2015, 9(2): 139-145.
[8] Farhad Sahebjam,John M. Vierling. Autoimmune hepatitis[J]. Front. Med., 2015, 9(2): 187-219.
[9] Guanghua Rong,Wenlin Bai,Zheng Dong,Chunping Wang,Yinying Lu,Zhen Zeng,Jianhui Qu,Min Lou,Hong Wang,Xudong Gao,Xiujuan Chang,Linjing An,Yan Chen,Yongping Yang. Cryotherapy for cirrhosis-based hepatocellular carcinoma: a single center experience from 1595 treated cases[J]. Front. Med., 2015, 9(1): 63-71.
[10] Yingchen Li,Guoheng Hu,Qilai Cheng. Implantation of human umbilical cord mesenchymal stem cells for ischemic stroke: perspectives and challenges[J]. Front. Med., 2015, 9(1): 20-29.
[11] Hai Wang,Qian Zhang,Xiangdong Fang. Transcriptomics and proteomics in stem cell research[J]. Front. Med., 2014, 8(4): 433-444.
[12] Jonathan Skupsky,Ke-Qin Hu. Current hepatitis B treatment guidelines and future research directions[J]. Front. Med., 2014, 8(2): 145-157.
[13] Bao-Zhu Yuan,Junzhi Wang. The regulatory sciences for stem cell-based medicinal products[J]. Front. Med., 2014, 8(2): 190-200.
[14] Marielle Reataza,David K. Imagawa. Advances in managing hepatocellular carcinoma[J]. Front. Med., 2014, 8(2): 175-189.
[15] James S. Park,Calvin Pan. Current recommendations of managing HBV infection in preconception or pregnancy[J]. Front. Med., 2014, 8(2): 158-165.
Full text